Barclays PLC Purchases New Holdings in Pharvaris (NASDAQ:PHVS)

Barclays PLC bought a new stake in shares of Pharvaris (NASDAQ:PHVS) in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund bought 5,700 shares of the company’s stock, valued at approximately $106,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Jane Street Group LLC bought a new stake in shares of Pharvaris during the 3rd quarter valued at $526,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in shares of Pharvaris during the 3rd quarter valued at $906,000. State Street Corp bought a new stake in shares of Pharvaris during the 3rd quarter valued at $1,000,000. Geode Capital Management LLC raised its position in shares of Pharvaris by 18.4% during the 3rd quarter. Geode Capital Management LLC now owns 36,977 shares of the company’s stock valued at $685,000 after acquiring an additional 5,753 shares during the last quarter. Finally, Novo Holdings A S raised its position in shares of Pharvaris by 47.7% during the 2nd quarter. Novo Holdings A S now owns 1,725,000 shares of the company’s stock valued at $32,430,000 after acquiring an additional 556,970 shares during the last quarter.

Pharvaris Stock Performance

Shares of Pharvaris stock opened at $19.32 on Friday. The firm has a fifty day moving average of $19.37 and a two-hundred day moving average of $19.35. The stock has a market capitalization of $1.01 billion, a price-to-earnings ratio of -6.90 and a beta of -3.06. Pharvaris has a 52 week low of $15.21 and a 52 week high of $33.00.

Pharvaris Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.